The Sinovac Biotech coronavirus vaccine acquired by Hong Kong has attained a “quite desirable” protection rate, a leading government pandemic adviser said on Friday, just hours after final-stage trial data from the mainland-based drug maker was revealed in Brazil.The remarks by Professor David Hui Shu-cheong, a member of the administration’s advisory panel on Covid-19 vaccines, followed authorities in the South American country announcing that CoronaVac – the drug’s name – had an efficacy rate…


READ  New Jersey hopes to reopen gyms, barbers in a 'matter of weeks,' Gov. Phil Murphy says


Please enter your comment!
Please enter your name here